Luxbright AB (LXB) AI Stock Analysis

Luxbright AB

(Nasdaq OMX AB:LXB)

Select Model

Rating:48Neutral

Price Target:SEK 5.00▼(-28.57% Downside)

Action:reiterated

Date:10/21/26

The score is primarily held back by weak financial performance—ongoing heavy losses, unstable margins, and sustained cash burn—despite the benefit of minimal leverage. Technical indicators are moderately supportive in the near term (price above 20/50 DMA and positive MACD), but the longer-term trend remains negative (below 100/200 DMA). Valuation is constrained by losses (negative P/E) and the absence of a dividend yield.

Positive Factors

Specialized X-ray technologyA focused product platform in compact X-ray generation gives Luxbright a defined commercial direction across industrial inspection and imaging use cases. Continued development and commercialization could support recurring product adoption if the technology translates into broader customer and system-integrator demand.

Negative Factors

Persistent unprofitabilityPersistent net losses and deeply negative operating results show that commercialization has not yet produced an economically sustainable business. Continued losses can erode equity, restrict investment capacity, and make future growth dependent on improved execution rather than sales expansion alone.

Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 12.65M
Dividend Yield: ―
Average Volume (3M): 260.33K
Price to Earnings (P/E): -0.3
Beta (1Y): -0.37
Revenue Growth: -13.46%
EPS Growth: 4.76%
Country: Sweden
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Luxbright AB Business Overview & Revenue Model

Company Description

Luxbright AB (publ), a technology-driven enterprise headquartered in Gothenburg, Sweden, specializes in engineering and marketing X-ray tubes, generators, and comprehensive X-ray systems. Established in 2012, the company's primary focus is on providi...

How the Company Makes Money

Luxbright AB’s revenue model is based on monetizing its X-ray source technology through sales and commercialization of products and related offerings. The primary revenue stream is expected to be direct revenue from delivering X-ray sources and/or in...

Luxbright AB Financial Statement Overview

Summary

Revenue momentum has improved recently, but the overall financial picture is weak due to large, persistent net losses, deeply negative operating results, volatile/negative gross margins in some years, and consistently negative operating cash flow and free cash flow. A low-debt balance sheet is a key stabilizer, but negative returns on equity underscore unprofitable use of capital.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

14Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.35M	11.41M	9.02M	854.70K	811.70K	729.00K
Gross Profit	-38.22M	-21.37M	8.88M	-2.80M	189.12K	1.98M
EBITDA	-19.23M	-16.76M	-15.72M	-23.87M	-20.47M	-17.63M
Net Income	-21.51M	-19.46M	-17.72M	-25.38M	-21.13M	-18.10M
Balance Sheet
Total Assets	32.25M	39.38M	42.66M	40.69M	31.19M	23.99M
Cash, Cash Equivalents and Short-Term Investments	362.00K	5.29M	12.36M	14.04M	7.60M	7.51M
Total Debt	3.24M	4.56M	254.19K	206.02K	588.34K	1.10M
Total Liabilities	8.85M	12.49M	8.46M	7.00M	3.33M	3.36M
Stockholders Equity	23.41M	26.89M	34.20M	33.69M	27.86M	20.63M
Cash Flow
Free Cash Flow	0	-19.87M	-16.52M	-20.39M	-20.64M	-17.14M
Operating Cash Flow	-20.93M	-19.87M	-16.52M	-20.39M	-20.64M	-17.14M
Investing Cash Flow	-2.92M	-3.65M	-3.44M	-3.99M	-7.15M	-4.15M
Financing Cash Flow	7.89M	16.46M	18.28M	30.82M	27.88M	-708.00K

Luxbright AB Technical Analysis

Technical Analysis SentimentNegative

Last Price7.00

Price Trends

50DMA5.63Negative

100DMA7.95Negative

200DMA18.12Negative

Market Momentum

MACD-0.12Positive

RSI43.75Neutral

STOCH6.80Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 7.00 is above the 20-day moving average (MA) of 6.48, above the 50-day MA of 5.63, and below the 200-day MA of 18.12, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 43.75 is Neutral, neither overbought nor oversold. The STOCH value of 6.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.

Luxbright AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:LXB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:PAX	57Neutral	SEK 1.54B	-303.85	-1.22%	―	34.05%	-144.96%
SE:BACTI.B	53Neutral	SEK 560.70M	88.89	1.93%	―	-0.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:LXB	48Neutral	SEK 12.65M	-0.33	-85.54%	―	-13.46%	4.76%
SE:SDOS	45Neutral	SEK 39.91M	-4.57	―	―	-19.44%	-475.48%
SE:SPEC	40Underperform	SEK 20.68M	-0.12	-57.15%	―	―	16.02%
SE:SCIB	39Underperform	SEK 174.38M	-0.78	-303.61%	―	51.21%	42.24%

* Healthcare Sector Average

Performance Comparison

SE:LXB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:LXB	Luxbright AB	5.22	-65.10	-92.58%
SE:PAX	Paxman AB	66.30	0.10	0.15%
SE:SCIB	SciBase Holding AB	12.35	-11.82	-48.90%
SE:SPEC	SpectraCure AB	0.01	-0.14	-90.73%
SE:BACTI.B	Bactiguard Holding AB	16.00	-0.20	-1.23%
SE:SDOS	ScandiDos AB	0.56	-0.50	-47.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 21, 2026

Luxbright AB AI Stock Analysis